News - Swedish Orphan Biovitrum, Oncology


Popular Filters

SOBI updates on Kepivance and SOB1002 development

SOBI updates on Kepivance and SOB1002 development


At its Capital Market Day event on November 5, Swedish Orphan Biovitrum shared information regarding…

Inflammatory diseasesKepivanceKiobrinaOncologyPharmaceuticalResearchSOB1002SobiSwedish Orphan Biovitrum

SOBI restructures Kineret and Kepivance deals


Swedish Orphan Biovitrum (STO: SOBI) said this morning that it has acquired the full rights to develop…

AmgenAnti-Arthritics/RheumaticsBiotechnologyKepivanceKineretLicensingOncologyPharmaceuticalRare diseasesSwedish Orphan Biovitrum

SOBI to distribute Exelixis' cancer drug Cometriq in EU


US biotech firm Exelixis (Nasdaq: EXEL) has entered into a three-year with Swedish Orphan Biovitrum (STO:…

BiotechnologyCometriqEuropeExelixisLicensingOncologySobiSwedish Orphan Biovitrum

SOBI gains distribution rights for Megace, Monopril, Cefzil and Duricef from PharmaSwiss


Swedish Orphan Biovitrum (STO: SOBI) says that it has entered into a distribution agreement with privately-held…

Antibiotics and Infectious diseasesCardio-vascularCefzilDuricefEuropeLicensingMegaceMonoprilOncologyPharmaceuticalPharmaSwissSobiSwedish Orphan Biovitrum

Back to top